Overview

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

Status:
COMPLETED
Trial end date:
2025-07-18
Target enrollment:
Participant gender:
Summary
The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.
Phase:
PHASE1
Details
Lead Sponsor:
Nanexa AB
Collaborator:
Profil Institut für Stoffwechselforschung GmbH